Nautilus, Inc.
NNYSE:NLSCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- Address
- Similar Companies
- Business
Company News
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
Red Canyon Initiates First Diamond Drill Program on its Nautilus Copper-Gold Target
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
Guardian Pharmacy Services Acquires Assets of Tennessee-Based Nautilus Pharmacy
Nautilus Biotechnology: Contrarian Proteoformics Play After The Recent Pullback
Nautilus Biotechnology Q2 Earnings Call Highlights
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
NLS Pharmaceutics Ltd. and Kadimastem Ltd.
NLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon Labs
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with Kadimastem
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025